anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Abusive head trauma (AHT) is one of the most devastating forms of pediatric traumatic brain injury (TBI). It commonly presents with seizures, which may contribute to poor neurological outcome following trauma. Noninvasive near-infrared spectroscopy (NIRS) neuromonitoring may provide information on cerebral oxygenation and perfusion. In this study, the authors evaluated whether NIRS regional cerebral oxygen saturation (rSO2) values were associated with seizure activity confirmed by electroencephalography (EEG) and whether NIRS neuromonitoring could aid in seizure detection in patients with severe AHT.
METHODS: The authors retrospectively analyzed pediatric patients aged ≤ 18 years who were admitted to a quaternary urban pediatric hospital from 2016 to 2022 with severe AHT, who received NIRS and EEG monitoring during their hospital course. They evaluated clinical presentation and hospital course, including imaging findings, EEG findings, and NIRS rSO2 values.
RESULTS: Nineteen patients with severe AHT were monitored with both EEG and NIRS. The median age was 3.4 months, and 14 patients experienced seizures confirmed by EEG. On average, rSO2 values before, during, and after seizure did not differ significantly. However, within individual patients, bilateral regional NIRS rSO2 (bilateral forehead region) was seen to rise in the hour preceding seizure activity and during periods of frequent seizure activity, confirmed by EEG in the bilateral frontal-midline brain regions.
CONCLUSIONS: To the best of the authors' knowledge, this is the largest study to analyze NIRS and seizures confirmed by EEG in the severe AHT population. The relationship between NIRS values and seizures in this series of pediatric patients with severe AHT suggests that, overall, regional NIRS cannot predict early seizures. However, increased cerebral oxygenation preceding seizure activity and during seizure activity may be detected by regional NIRS in certain patients with local seizure activity. Future studies with larger sample sizes may help elucidate the relationship between seizures and cerebral oxygenation in different regions in severe pediatric AHT.
OBJECTIVE: Complex endovascular abdominal aortic aneurysm (AAA) repair techniques have evolved over the last decade, yet patterns of physician and hospital system adoption of fenestrated endovascular aneurysm repair (FEVAR) remain poorly defined. We investigated clinical outcomes, use trends, and surgeon and hospital experience for FEVAR in a large community hospital system.
METHODS: We conducted a retrospective cohort study of all FEVAR procedures within our 5-state hospital system between April 2012 and June 2021. AAA repair volumes (open, EVAR, and FEVAR) were captured at the hospital and surgeon levels using Current Procedural Terminology and International Classification of Diseases codes. Clinical and outcomes data were collected for FEVAR patients. To consider if surgeon or hospital experience influenced outcomes, sequential case number was used to divide patients into surgeon experience and hospital experience groups. Inverse probability weighted and generalized linear mixed models, adjusted for demographics and comorbidities, were built to examine risk-adjusted outcomes for surgeon and hospital experience groups.
RESULTS: Of 3850 patients treated with AAA procedures of any kind between 2012 and 2021, 160 (4.2%) underwent FEVAR. FEVAR procedures were performed by 34 different surgeons at 12 hospitals, with intraoperative complications and unplanned adjunctive procedures occurring in 18.8% (n = 30) and 19.4% (n = 31) of patients, respectively. Among FEVAR patients, in-hospital mortality was 1.3% (n = 2) and postoperative morbidity was 16.9% (n = 27). Renal function decline occurred postoperatively in 5.1% of patients. Early (<30 day) postoperative endoleaks occurred in 15.3% of patients (n = 21). Target vessel patency was 95.6% on initial postoperative imaging. Surgeon and hospital experience had a small positive impact on outcomes after the first one to three cases. Significant decreases in operative time, fluoroscopy time, and estimated blood loss were observed with increased surgeon experience, relative to a surgeon's first case (P < .05). There were lower odds of intraoperative complications after a surgeon's first case (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.03-0.77, for cases 2-3) or after a hospital's first one to three cases (OR, 0.19; 95% CI, 0.04-0.89, for cases 4-8; OR, 0.12; 95% CI, 0.03-0.55 for cases 9-49).
CONCLUSIONS: Clinical outcomes of FEVAR across our hospital system compare favorably with previously published reports. Although system-wide FEVAR adoption increased 3-fold over the last decade, FEVAR continued to be performed by a minority of hospitals in our system. The results from this cohort demonstrate low rates of adverse events, high rates of technical efficiency, and a small impact of surgeon and hospital experience, thereby supporting this advanced endovascular technology as a safe, efficacious, and generalizable treatment alternative to open repair for patients with complex aortic anatomy.
The rapid development of digital technology has radically changed people's lives. Simultaneously, as the population is rapidly aging, academic research is focusing on the use of Internet technology to improve middle-aged and older people's health, particularly owing to the popularity of mobile networks, which has further increased the population's accessibility to the Internet. However, related studies have not yet reached a consensus. Herein, empirical analysis of the influence of mobile Internet use on the subjective health and chronic disease status of individuals in their Middle Ages and above was conducted utilizing ordered logit, propensity score matching (PSM), and ordered probit models with data from the 2020 China Health and Retirement Longitudinal Study. The study aimed to provide a theoretical basis and reference for exploring technological advances to empower the development of a healthy Chinese population and to advance the process of healthy aging. The health of middle-aged and older adults mobile Internet users was greatly improved, according to our findings. Further, the use of mobile Internet by these persons resulted in improvements to both their self-assessed health and the state of their chronic diseases. As per the findings of the heterogeneity analysis, the impact of mobile Internet use was shown to be more pronounced on the well-being of middle-aged persons aged 45-60 years compared to those aged ≥ 60 years. Further, the endogeneity test revealed that the PSM model could better eliminate bias in sample selection. The results suggest that the estimates are more robust after eliminating endogeneity, and that failure to disentangle sample selectivity bias would overestimate not only the facilitating effect of mobile Internet use on the self-assessed health impacts of middle-aged and older adults, but also the ameliorating effect of mobile Internet use on the chronic diseases of middle-aged and older adults. The results of the mechanistic analysis suggest that social engagement is an important mediating mechanism between mobile Internet use and the health of middle-aged and older adults. This implies that mobile Internet use increases opportunities for social participation among middle-aged and older adults, thereby improving their health.
A two-way audiovisual communication device with multiple audio and video subsystems. In one embodiment, the device includes a wheeled cart that supports a dock for a tablet computing device that includes a tablet camera, a tablet display, and a tablet microphone. The device also includes a cart camera, a cart speaker, and a cart microphone. The device may be coupled to a network and accessible to other devices on the network to allow a two-way audiovisual session to take place between remote parties. The device may operate in two modes: In a first mode, the tablet is mated with the dock and the remote device receives video from the pan-tilt-zoom camera and audio from the cart microphone. In a second mode, the tablet is removed from the dock and the remote device receives video from the tablet camera and audio from the tablet microphone. In both modes, the tablet monitor displays video from the remote device.
Silica nanoparticle (SiNP) exposure induces severe pulmonary inflammation and fibrosis, but the pathogenesis remains unclear, and effective therapies are currently lacking. To explore the mechanism underlying SiNPs-induced pulmonary fibrosis, we constructed in vivo silica exposure animal models and in vitro models of silica-induced macrophage pyroptosis and fibroblast transdifferentiation. We found that SiNP exposure elicits upregulation of pulmonary proteins associated with pyroptosis, including NLRP3, ASC, IL-1β, and GSDMD, while the immunofluorescence staining co-localized NLRP3 and GSDMD with macrophage-specific biomarker F4/80 in silica-exposed lung tissues. However, the NLRP3 inhibitor MCC950 and classical anti-fibrosis drug pirfenidone (PFD) were found to be able to alleviate silica-induced collagen deposition in the lungs. In in vitro studies, we exposed the fibroblast to a conditioned medium from silica-induced pyroptotic macrophages and found enhanced expression of α-SMA, suggesting increased transdifferentiation of fibroblast to myofibroblast. In line with in vivo studies, the combined treatment of MCC950 and PFD was demonstrated to inhibit the expression of α-SMA and attenuate fibroblast transdifferentiation. Mechanistically, we adopted high throughput RNA sequencing on fibroblast with different treatments and found activated signaling of relaxin and osteoclast differentiation pathways, where the expression of the dysregulated genes in these two pathways was examined and found to be consistently altered both in vitro and in vivo. Collectively, our study demonstrates that SiNP exposure induces macrophage pyroptosis, which subsequently causes fibroblast transdifferentiation to myofibroblasts, in which the relaxin and osteoclast differentiation signaling pathways play crucial roles. These findings may provide valuable references for developing new therapies for pulmonary fibrosis.
PURPOSE:A binder, containing gelan gum as a principal material, advantageous for industrial production as a binder for cataplasm, ointment, suppository, etc., and having high binding effect. CONSTITUTION:A binder for formulating medicines containing gelan gum as a principal material. Gelatin, colloid similar thereto or aqueous gel thereof has been normally used as a binder used in cataplasm, ointment, suppository, etc., but there are disadvantages, e.g. gelatin, etc., outflows in cataplasm, etc., at a high temperature in the summer season to reduce the drug efficacy for a part to be applied since the flow starting point of the gelatin is as low as about 250 deg.C. Since the sol formation temperature of the principal material gelan gun is >=70 deg.C, the heat stability is much better than that of the gelatin and thermal decomposition is hardly caused. The resultant pharmaceutical using the above-mentioned binder has very high heat stability and acid and alkali resistance and further is readily used without toxicity to human bodies.
Adipose-derived stem cells (ADSCs) have been demonstrated to improve the microenvironment after a stroke. Increasing studies have confirmed that hypoxia pretreatment of ADSCs resulted in a better therapeutic effect, but the mechanism of treatment is unclear. We isolated ADSCs and exosomes. Then, constructed a middle cerebral artery occlusion (MCAO) mice model. High-throughput sequencing was used to identify the differential expression of circRNA. Immunofluorescence and ELISAs were used to detect the therapeutic effects of ADSC exosomes on MCAO. The luciferase reporter assay was used to detect the interaction relationships among circRNA-Ptpn4, miR-153-3p, and Nrf2. This study showed that exosomes from hypoxia pretreatment of ADSCs had significant effects in promoting functional recovery following in vivo MCAO, through suppressed inflammatory factor expression, and shifting the microglial from M1 to M2 polarization activation. The results showed that circRNA-Ptpn4 was highly expressed during hypoxia pretreatment of ADSCs exosomes. Exosomes from circ-Ptpn4-modified ADSCs had a greater ability to promote functional recovery. The circ-Ptpn4 delivered from ADSC exosomes induced microglia/macrophage polarization from M1 to M2 by suppressing miR-153-3p and enhancing Nrf2 expressions. Taken together, the results showed that exosomes from circRNA-Ptpn4 modified ADSC treatment repaired nerve damage caused by cerebral infarction by inducing microglial M1/M2 polarization.
This randomised controlled clinical intervention study will take place across three European sites; the German Sport University Cologne, Germany, University of Nijmegen, The Netherlands and Trinity College Dublin, Ireland. Seventy-five previously sedentary patients with a clinical diagnosis of MCI will be recruited at each site. Participants will be randomised to one of three intervention arms. One group will receive a standardised one-year extensive aerobic exercise intervention (3 units of 45min / week). The second group will complete stretching and toning (non-aerobic) exercise (3 units of 45min / week) and the third group will receive usual care. Change in all outcomes will be measured at baseline (T0), after six months (T1) and after 12 months (T2).
PROBLEM TO BE SOLVED: To obtain a new arylalkane derivative having a stimulating action on a motilin receptor, exhibiting activating action on enterokinesis, effective for treating gastrointestinal diseases followed by enterokinesis insufficiency. SOLUTION: This arylalkane derivative is shown by formula I ((n) is an integer of 1 to 4; A is a benzene ring, etc.; R<1> and R<2> are each H, H, a 1-3C alkyl, etc.; X is CH or N; D is a halogen, etc.) such as N,N-dimethyl-4-(3,5- diphenyl-3-pentenyl)aniline. The compound of formula I in which D is CH is obtained by condensing a compound of formula II with a compound of formula III.
PURPOSE: A bacteriophage SAP26 which induces apoptosis of Staphylococcus aureus is provided to effectively induce bacteria apoptosis and to ensure stability. CONSTITUTION: A Siphoviridae bacteriophage SAP26 has an apoptotic ability to Staphylococcus aureus and has genome of sequence number 1. The bacteriophage has deposit number KCTC 11665BP. A pharmaceutical composition for treating diseases caused by Staphylococcus aureus contains the bacteriophage SAP26 as an active ingredient. An antibiotic contains bacteriophage SAP26. A disinfectant contains bacteriophage SAP26.
Participants received 200 milligrams (mg) LY3023414 orally twice daily (BID) during the initial week to assess pharmacokinetics (PK). Thereafter, participants received 200 mg of LY3023414 BID in combination with 160 mg of enzalutamide QD beginning Cycle 1 Day 1. A treatment cycle was defined as 28 days.
Patients receive entinostat PO on days 1, 8, 15, and 22 and molibresib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention relates to a vitamin D-insulin nano sustained-release transdermal preparation and a preparation method thereof. The invention relates to a vitamin D-insulin nano transdermal drug delivery preparation which is prepared by taking vitamin D as a carrier and insulin as a main active ingredient to be assembled together to form a nano solution, and mixing the nano solution with a humectant, a transdermal penetration enhancer, a preservative and the like. The long-acting sustained-release preparation prepared by wrapping insulin with vitamin D by using nanotechnology has the advantages of large specific surface area, high stability and large surface energy. Meanwhile, the vitamin D nano-microspheres have good lipid solubility, and can accelerate the drug to penetrate through the skin and be utilized by the organism. The invention combines and utilizes vitamin D and insulin, can slowly release and reduce blood sugar, can improve the function of islet beta cells, and has wide physiological action. The invention realizes painless, slow release and convenient administration, and has simple preparation method and low production cost.
The invention provides positively-charged water-soluble diclofenac prodrugs with high skin penetration velocity. In a ''structural formula 1'' of a general formula (1), novel positively-charged water-soluble diclofenac prodrugs are designed and synthesized. The compounds as shown in the above-mentioned ''structural formula 1'' of the general formula (1) can be synthesized by reaction of functionalized derivatives (like acid halides or mixed anhydrides) of diclofenac with proper alcohol, thioalcohol or amine. Positively-charged amino groups on prodrug molecules greatly improve the solubility of a drug, and promote the drug to enter cytoplasm by combination with negative charges on biological membrane phosphate terminal groups. Experimental results show that the prodrug, i.e., 2-[(2,6-dichlorophenyl)amino]phenylacetate diethylaminoethyl acetate, has a human skin penetration velocity which is nearly 250 times as fast as the human skin penetration velocity of the prodrugs, i.e., 2-[(2,6-dichlorophenyl)amino]phenylacetate (diclofenac) and 2-[(2,6-dichlorophenyl)amino]phenylacetate ethyl. In plasma, more than 90% of the prodrugs can return to a parent drug in a few minutes. The prodrugs can be applied in medicine to treat human or animal states that any diclofenac can treat; in treatment, oral administration and transdermal administration are available, so that most of side effects of diclofenac are avoided, wherein the most significant side effects comprise gastrointestinal discomforts like indigestion, bleeding in stomach and duodenal, gastric ulcer and gastritis. Through a controlled release transdermal administration system of the prodrugs, the plasma drug concentration is stabilized in an optimal therapeutic level, so the treatment effects are improved, and the side effects of diclofenac are decreased.
IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
Overdose has not been observed in the FINTEPLA clinical trial program. However, overdose of fenfluramine, the active ingredient in FINTEPLA, has been reported at higher doses than those included in the clinical trial program. Some of the cases were fatal. Events reported after overdose include mydriasis, tachycardia, flushing, tremors/twitching/muscle spasms, agitation/restlessness/anxiety, increased muscle tone/rigor/opisthotonos, respiratory distress or failure, and seizure. Seizure, coma, and cardiorespiratory arrest were reported in most of the fatal overdoses.

There is no available specific antidote to the overdose reactions of FINTEPLA. In the event of overdose, standard medical practice for the management of drug overdosage should be used. An adequate airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm and vital sign measurement is recommended. A certified poison control center should be contacted for updated information on the management of overdose with FINTEPLA.
BACKGROUND AND OBJECTIVE: Hepatic portal venous gas(HPVG) represents a rare radiographic phenomenon frequently linked to intestinal necrosis, historically deemed to need immediate surgical intervention. The pivotal query arises about the imperative of urgent surgery when a patient manifests HPVG after gastrointestinal surgery. This inquiry seeks to elucidate whether emergent surgical measures remain a requisite in such cases.
METHODS: The investigation into 14 cases of HPVG after gastrointestinal procedures was conducted through a comprehensive review of relevant literature. This methodological approach contributes to a nuanced understanding of HPVG occurrences following gastrointestinal surgery, informing clinical considerations and potential therapeutic strategies.
RESULTS: Among the 14 patients, 12 recovered and 2 died. 6 patients underwent surgical exploration, 4 with negative findings and recovered. 8 cases received conservative treatment, resulting in improvement for 5, and 1 initially treated conservatively, revealed perforation during later surgical exploration, leading to improvement, 1 case ended in mortality.
CONCLUSION: After gastrointestinal surgery, in Computed Tomography (CT) imaging, the coexistence of HPVG and gastrointestinal dilatation, without signs of peritoneal irritation on abdominal examination, may suggest HPVG due to acute gastrointestinal injury, intestinal gas, and displacement of gas-producing bacteria. These patients can be managed conservatively under close supervision. In cases where HPVG coexists with gastrointestinal dilatation and Pneumatosis intestinalis (PI) without signs of peritoneal irritation, conservative treatment may be continued under close supervision. However, if progressive exacerbation occurs despite close monitoring and the aforementioned treatments, timely surgical exploration is deemed necessary. When HPVG is combined with signs of peritoneal irritation, prompt laparotomy and exploration are preferred.
This is a ambispective, multi-surgeon, single site, consecutive case series. Data collection will occur in two phases. Retrospective data collection will occur upon subject identification, and data will be collected from the site's medical records for minimum of 50 subjects who have undergone soft tissue to bone fixation with the Grappler® Interference Screw System. Data will be collected from the subjects' pre-op visits, intra-op visits, 7 week post-op follow-up visits (± 4 weeks), and 6 month post-op follow-up visits (± 4 weeks). The subject must have adequate radiographic and medical records for the minimum follow up requirement of 6 months. Prospective data collection will occur upon subject's provision of written informed consent, and data will be collected from patient reported outcomes (PRO's).
Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
Fifteen women were selected for this experiment in the form of a randomized crossover study. Measurements were taken by leg jumps over 5 obstacles 125 cm apart. The pre-test was performed twice with a two-minute rest between each trial. Immediately after finishing the second trial, a randomly selected half of the probands performed posterior chain facilitation using a foam roller, facilitating first the left leg, then the right leg and finally spinal erectors. Rolling was performed with a sense of maximal intensity and at a high rolling speed across the full length and width of the muscle with both cranial and caudal rolling directions. Facilitation was performed on each muscle group in the distoproximal direction. Immediately following the intervention, a post-test was performed a total of 3 times, 1 minute after the intervention, 3 minutes after the intervention and 5 minutes after the intervention. The control measurement was performed the same way as the intervention, but the control group of probands rested in a resting sitting position for 4 minutes instead of foam rolling. After one week, a second measurement followed, where the original control group underwent the intervention measurement and vice versa.

The Optojump instrument (Microgate, Bolzano, Italy) was used to obtain the resistance and flight phase data. A video recording (GoPro HERO 9) was taken of the skipping procedure, from which photographs were taken over each obstacle at the moment of the greatest trunk tilt (the junction of the trochanter major and the external auditory canal exit) from the vertical axis.